Bernstein精選:SSE、Shell股價看俏!

投行Bernstein睇好SSE同Shell,話佢哋夠穩陣,派息又唔錯。SSE增長潛力大,Shell回購計劃吸引。咁樣嘅市況,揀佢哋係咪真係穩陣之選?
Read More

Genmab遭降評級:專利到期陰影,股價恐承壓?

Bernstein睇淡Genmab前景,專利藥到期、收購成疑。收入大跌預期下,目標價插水式下調。Genmab仲有無翻身機會,定係蟹硬呢?
Read More